CAR T Cell Therapy Market (5th Edition): Industry Trends and Global Forecasts, Till 2035: Distribution by Target Indication

CAR T Cell Therapy Market (5th Edition): Industry Trends and Global Forecasts, Till 2035: Distribution by Target Indication

The CAR T Cell Therapy Market is valued at USD 4.6 billion in 2024 growing at a CAGR of 20% during the forecast period 2024-2035

Cancer stands as a leading cause of mortality worldwide, with the World Health Organization (WHO) reporting 10 million cancer-related deaths in 2020 alone. Projections suggest that by 2040, the global cancer burden will escalate, adding an estimated 27.5 million new cases, placing immense physical, emotional, and financial strain on affected individuals, families, communities, and national health systems. Currently, conventional treatment modalities such as chemotherapy, radiation therapy, and surgery are utilized for various cancers. However, despite the array of treatment options aimed at controlling disease progression and halting the spread of malignant cells, achieving lasting remission remains challenging. To cater to the limitations of conventional treatments, active initiatives have been launched to develop more targeted anti-cancer therapies. Among these, CAR T cell therapies have emerged as a promising option due to their ability to eliminate tumor cells with minimal treatment-related side effects. Immunotherapies leverage the body's immune system or its components to combat cancer. Various classes of immunotherapies, including therapeutic cancer vaccines, oncolytic viruses, cytokines, immune checkpoint inhibitors, and certain whole cell-based therapies, have emerged as an alternative for cancer management and treatment.

CAR-T cell therapy, a recent addition to anticancer interventions, has shown significant success alongside targeted antibody-based therapeutics like monoclonal and conjugated antibodies. This highly specific form of cell therapy, harnessing the versatile effector machinery of the human immune system, has revolutionized cancer treatment globally. Ongoing research in this field continues to uncover novel molecular targets, bolstering the research pipelines of companies in this domain. With a growing number of CAR T cell therapies under development and entering the market, the CAR T cell therapy market is poised to become one of the most valuable segments within the biopharmaceutical industry.



Key Market Segments

Target Indication

Acute Myeloid Leukemia

Acute Lymphoblastic Leukemia

Chronic Lymphocytic Leukemia

Generalized Myasthenia Gravis

Hodgkin's Lymphoma

Multiple Myeloma

Non-Hodgkin's Lymphoma

Ovarian Cancer

Renal Cell Carcinoma

Others

Target Antigen

CD19

BCMA

CD19 / CD22

Others

Key Geographical Regions

North America

Europe

Asia-Pacific

Latin America

Middle East and North Africa

Rest of the World

Research Coverage:

A detailed analysis of the current market landscape of CAR-T cell therapies with respect to the type of developer (industry and non-industry), phase of development (approved, phase III, phase II / III, phase II, phase I / II, phase I, clinical (phase unknown), preclinical), therapeutic area (oncological disorders, non-oncological disorders and undisclosed), key target indication (acute lymphoblastic leukemia, B-cell lymphoma, multiple myeloma, non-Hodgkin lymphoma, acute myeloid leukemia, hepatocellular carcinoma, diffuse large B-cell lymphoma, pancreatic cancer, gastric cancer, lung cancer, mantle cell lymphoma, ovarian cancer, breast cancer and follicular lymphoma), key target antigen (CD19, BCMA, CD19 / CD22, GPC3, NY-ESO-1 and others), source of T-cells (autologous and allogeneic), route of administration (intravenous, intratumoral, intraperitoneal, intrapleural, intracranial and others), dose frequency (single dose, multiple doses and split doses), patient segment (children, adults and seniors) and type of therapy (monotherapy and combination therapy). Additionally, it highlights the most active industry and non-industry players (in terms of number of pipeline candidates) engaged in the development of CAR T cell therapy. Further, this chapter also includes developer landscape analysis based on the relevant parameters, including year of establishment, company size (small, mid-sized and large) and location of headquarters (North America, Europe and Asia-Pacific).

Comprehensive assessment of key insights derived from the study featuring a competitive analysis, highlighting the popular target antigens related to hematological malignancies and solid tumors. Additionally, it includes CAR construct analysis of clinical-stage CAR T cell therapies based on the generation of CAR (first generation, second generation, third generation and fourth generation), type of binding domain (murine, humanized, fully human and rabbit derived), type of virus used (lentivirus and retrovirus), type of gene transfer method used (transduction and transfection) and type of co-stimulatory domain used.

A comprehensive assessment of the completed, ongoing and planned clinical studies related to CAR T cell therapies, based on several relevant parameters, such as trial registration year, enrolled patient population, trial recruitment status, trial phase, target patient segment, type of sponsor / collaborator, most active players and regional distribution of trials.

An insightful analysis highlighting the key opinion leaders (KOLs) featuring an assessment of the principal investigators of clinical trials related to CAR-T therapies, considering them to be KOLs, who are actively involved in R&D of CAR T cell therapies. In addition, the chapter presents an analysis, comparing the relative expertise of KOLs based on a proprietary scoring criterion and that of a third party.

Elaborate company profiles of leading players in this domain. Each company profile includes a company overview and brief description of the product portfolio, technology portfolio, recent developments related to CAR-T cell therapies and manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.

An analysis of different types of partnership that have been inked between several stakeholders in this domain, on various type of partnership such as, R&D agreements, license agreements (specific to technology platforms and therapy candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements, joint ventures and others.

An analysis of the funding and investment analysis that have been made into CAR T cell therapy companies that have proprietary therapies / technologies, including seed financing, venture capital financing, capital raised from IPOs and subsequent offerings, grants and debt financing.

An in-depth analysis of patents related to CAR T cell therapies, filed / granted till 2022, based on several relevant parameters, such as type of patent (granted patents, patent applications and others), publication year, geographical distribution, Cooperative Patent Classification (CPC) symbols, emerging focus areas, type of applicant, leading players (on the basis of number of patents filed / granted) and patent benchmarking. In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.

A case study on manufacturing cell therapy products, highlighting the key challenges, and a detailed list of contract service providers and in-house manufacturers involved in this space.

An elaborate assessment of various factors that form the basis for the pricing of cell-based therapies. It features different models / approaches that a pharmaceutical company may choose to adopt to decide the price of a CAR-T cell therapy that is likely to be marketed in the coming years.

An in-depth analysis of various factors that can influence the growth of CAR T cell therapy market. It also features identification and analysis of key drivers, potential restraints, emerging opportunities, and existing challenges.

A detailed estimate of the current market size, opportunity and the future growth potential of the CAR T cell therapy market over the next 12 years. Based on multiple parameters, likely adoption trends and through primary validations, we have provided an informed estimate on the market evolution during the forecast period till 2035. The report also features the likely distribution of the current and forecasted opportunity within this market. Further, in order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

Comprehensive predictions of the current and future CAR T cell therapy market across type of target indication, such as non-Hodgkin lymphoma, multiple myeloma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, Hodgkin lymphoma, acute myeloid leukemia, ovarian cancer, generalized myasthenia gravis and renal cell carcinoma).

Comprehensive projections of the current and future CAR T-cell therapy market across type of target antigen, such as CD19, BCMA, CD19 / CD22 and others.

Detailed projections of the current and future CAR T cell therapy market across leading players.

Detailed projections of the current and future CAR T-cell therapy market across key geographical regions, such as North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa and Rest of the World.

A review of the key promotional strategies being adopted by the developers of the approved CAR T cell therapies, namely Tisagenlecleucel-T (KYMRIAH®), Axicabtagene ciloleucel (YESCARTA®), Brexucabtagene Autoleucel (TECARTUS™), Lisocabtagene maraleucel (Breyanzi®), Idecabtagene Vicleucel (Abecma™), Ciltacabtagene Autoleucel (CARVYKTI™) and others.

Key Benefits of Buying this Report

The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.

Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.

The report provides stakeholders with a pulse on the CAR T Cell Therapy Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Leading Market Companies

Alaunos Therapeutics

Autolus

Abelzeta Pharma

Bluebird Bio

Bristol Myers Squibb

Carsgen Therapeutics

Cellectis

Gilead Sciences

Innovative Cellular Therapeutics

Kuur Therapeutics

Noile-Immune Biotech

Novartis

Shanghai GeneChem

Sinobioway Cell Therapy

Takara Bio

Wellington Zhaotai Therapies